目的 评价天麻钩藤颗粒治疗原发性高血压（EHT）的经济性，以期为卫生医疗用药资源的合理配置提供参考依据。方法 本研究采用TreeAge Pro软件对天麻钩藤颗粒＋硝苯地平控释片（NCRT）vs单用NCRT干预EHT进行成本效果分析，干预周期为12周，并对结果进行敏感性分析和情境分析。结果 基础分析结果显示，两组的增量成本效果比（ICER）值为65.15元，即相比于单用NCRT，使用天麻钩藤颗粒联合NCRT每多获得1个单位的有效率，EHT患者需多花费65.15元；当患者的个人意愿支付价格高于65.15元时，天麻钩藤颗粒＋NCRT组具有经济性的概率优于单用NCRT组。敏感性分析结果验证了基础分析结果的稳健性，天麻钩藤颗粒组的临床疗效和NCRT组的用药成本对研究结果有较大影响，当患者的个人意愿支付价格高于64元时，具有更高经济性概率的干预方案同基础分析结果一致。结论 当个人意愿支付价格高于64元时，EHT患者选用天麻钩藤颗粒联合NCRT比单用NCRT在降低血压方面更具有经济性。
Objective To evaluate the economic efficiency of Tianma Gouteng Granules (TGG) in treatment of essential hypertension (EHT), so as to provide reference for rational allocation of medical medication resources. Methods TreeAge Pro software was used to analyze the cost-effectiveness of TGG + nifedipine controlled released tablets (NCRT) versus NCRT alone for EHT intervention. The intervention period was 12 weeks, and sensitivity analysis and situational analysis were performed on the results. Results The basic analysis results showed that the ICER of the two groups was 65.15 yuan. In other words, compared with NCRT alone, TGG combined with NCRT cost 65.15 yuan more for each additional unit of effective rate. When the patient's personal willingness to pay was higher than 65.15 yuan, the economic probability of TGG plus NCRT was better than that of conventional therapy alone. The results of sensitivity analysis verified the robustness of the results of the basic analysis. The clinical efficacy of TGG combined with NCRT group and treatment cost of the NCRT group had a great impact on the results of the study. When the patients' personal willingness to pay more than 64 yuan, the TGG combined with NCRT group with higher economic probability was consistent with the results of the basic analysis. Conclusion When the individual willing to pay more than 64 yuan, TGG combined with NCRT is more economical than NCRT alone in reducing blood pressure in EHT patients.